title: Reply to the letters to the editor 'Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by Diwakar et al.
authors.affiliation: Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen; German Cancer Consortium (DKTK), Heidelberg, Germany. Electronic address: bastian.schilling@uk-essen.de.
authors.forename: B
authors.initials: B
authors.lastname: Schilling
authors.affiliation: Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen; German Cancer Consortium (DKTK), Heidelberg, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Sondermann
authors.affiliation: Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen; German Cancer Consortium (DKTK), Heidelberg, Germany.
authors.forename: K G
authors.initials: KG
authors.lastname: Griewank
authors.affiliation: Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen; German Cancer Consortium (DKTK), Heidelberg, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Livingstone
authors.affiliation: Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen; German Cancer Consortium (DKTK), Heidelberg, Germany.
authors.forename: L
authors.initials: L
authors.lastname: Zimmer
authors.affiliation: Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen; German Cancer Consortium (DKTK), Heidelberg, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Hillen
authors.affiliation: Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen; German Cancer Consortium (DKTK), Heidelberg, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Schadendorf
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use*; D016131:Lymphocyte Subsets / Q000187:drug effects*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D010091:Oximes / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D007211:Indoles; D010091:Oximes; D013449:Sulfonamides